Immune Checkpoint Inhibitors – Access & Reimbursement – Detailed, Expanded Analysis – Top Five European Markets (EU)

Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This report focuses on: malignant melanoma, primarily the adjuvant setting, which has been newly penetrated by the immune checkpoint inhibitors; bladder cancer, for which reimbursement of the drug class under study is not proving to be straightforward; and, squamous cell carcinoma of the head and neck (SCCHN), an indication with few labeled treatments and high unmet need. As novel immune checkpoint inhibitor therapies prepare to enter the markets under study, and label expansions for existing treatments loom large on the horizon, optimal market access opportunities beckon in France, Germany, Italy, Spain, and the UK, but payer-imposed reimbursement restrictions and cost-containment strategies will increasingly play a pivotal role in shaping medical oncologists’ prescribing practices for these high-cost therapies, and manufacturers must be prepared to compromise in order to maximize return on investment.

QUESTIONS ANSWERED

  • What are the key driving forces and constraints that influence European payers’ reimbursement decisions for immune checkpoint inhibitors in malignant melanoma, bladder cancer, and SCCHN?
  • How do reimbursement policies at the national, regional, and local levels shape prescribing preferences? How do payers prioritize diminishing budgets and monitor immune checkpoint inhibitor prescribing accordingly?
  • Do interviewed payers and surveyed prescribers believe that efficacy of existing and emerging therapies justifies their cost? Which treatments do they think perform best on clinical and other attributes? How will prescribing patterns change with the launch of novel immune checkpoint inhibitors?
  • What can manufacturers do to encourage optimal P&R terms and to drive uptake? How might evolving healthcare reforms and cost-containment strategies affect reimbursement and product positioning? To what degree will payer policy impact prescribing?

PRODUCT DESCRIPTION

European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers to examine reimbursement dynamics and evaluate the impact of payer policy on prescribing behavior.

GEOGRAPHY

France, Germany, Italy, Spain, and United Kingdom

PRIMARY RESEARCH

  • Survey of 247 medical oncologists across the top 5 European markets (49-50 per country)
  • Interviews with 10 payers top 5 European markets (2 per country).

KEY DRUGS COVERED

Keytruda, Opdivo, Tecentriq, Yervoy, spartalizumab, Imfinzi, tremelimumab, Bavencio

CONTENT HIGHLIGHTS

  • Actionable recommendations to optimize market access
  • Market access success and stumbles
  • Market access roadblocks
  • Pricing and reimbursement dynamics
  • Impact of payer policy and coverage on prescribing
  • Market access outlook for emerging therapies

Table of contents

  • Immune Checkpoint Inhibitors - Access & Reimbursement - Detailed, Expanded Analysis - Top Five European Markets (EU)
    • Access & Reimbursement - Immune Checkpoint Inhibitors - Top Five European Markets - 2019